KN-002

About Kinaset Therapeutics

Kinaset Therapeutics is a private, preclinical-stage biotech developing KN-002, a novel inhaled therapeutic for severe asthma. The company's strategy leverages direct pulmonary delivery to target inflammation locally, aiming for a broad-spectrum anti-inflammatory effect that could treat patients regardless of their asthma phenotype. Founded in 2020 and headquartered in Boston, Kinaset is advancing towards clinical trials with a focus on creating a convenient, non-invasive treatment option for a significant unmet medical need. The company operates in the competitive respiratory therapeutics space with a small molecule approach.

Therapeutic Areas

Other Severe Asthma Drugs